Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $22.7 million.

  • Corcept Therapeutics' Net Cash Flow rose 17817.51% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.1 million, marking a year-over-year decrease of 15246.6%. This contributed to the annual value of -$7.9 million for FY2024, which is 11139.23% down from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Net Cash Flow is $22.7 million, which was up 17817.51% from $11.1 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Net Cash Flow high stood at $233.6 million for Q1 2023, and its period low was -$127.6 million during Q2 2023.
  • Its 5-year average for Net Cash Flow is $2.5 million, with a median of -$742000.0 in 2021.
  • In the last 5 years, Corcept Therapeutics' Net Cash Flow surged by 210768.19% in 2022 and then crashed by 50663.89% in 2023.
  • Corcept Therapeutics' Net Cash Flow (Quarter) stood at -$17.1 million in 2021, then skyrocketed by 194.23% to $16.1 million in 2022, then surged by 47.65% to $23.8 million in 2023, then tumbled by 138.29% to -$9.1 million in 2024, then surged by 349.76% to $22.7 million in 2025.
  • Its Net Cash Flow was $22.7 million in Q3 2025, compared to $11.1 million in Q2 2025 and -$37.8 million in Q1 2025.